Measurement of fractional exhaled nitric oxide in real-world clinical practice alters asthma treatment decisions

Assessment of asthma using clinical measures alone often fails to detect underlying airway inflammation. Fractional exhaled nitric oxide (FeNO) is a recognized biomarker of type 2 airway inflammation in asthma. Measurement of FeNO is instrumental in the assessment and management of patients with corticosteroid-sensitive asthma.

http://ift.tt/2Ezs9I6